Since human Her2 and canine Her2 have >90% homology and the Lm-based vaccine targeting human Her2/neu, ADXS31-164, had already been developed and successfully tested in mice, a small Phase I clinical trial consisting of 18 client-owned dogs was performed to determine the safety, tolerability, and efficacy of the Lm-based vaccine targeting Her2/neu, ADXS31-164, in canine osteosarcoma (73, 74). Here, ERBB2 is linked to osteosarcoma.